GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » Sale Of Investment

Telix Pharmaceuticals (STU:T3X) Sale Of Investment : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telix Pharmaceuticals Sale Of Investment?

Telix Pharmaceuticals's sale of investment for the six months ended in Dec. 2024 was €0.0 Mil. It means Telix Pharmaceuticals gained €0.0 Mil from selling investments. Telix Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Jun. 2024 ), Telix Pharmaceuticals gained the same money from selling investments in Dec. 2024 (€0.0 Mil).


Telix Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for Telix Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Sale Of Investment Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Telix Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Headlines

No Headlines